Press Release Q1 FY 2026-27 Results.

Date:- August 05, 2026 BSE Limited National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001 Mumbai - 400 051 BSE Script Code: 531599 NSE Symbol: FDC Sub: Press Release Q1 - FY 2026-27 Results Dear Sir/Ma’am, Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2026. Kindly take the same on record. Thanking you, Yours truly For FDC Limited Varsharani Katre Company Secretary & Legal Head M No.: FCS-8948 FDC Limited announces Q1 FY27 results Mumbai, August 5, 2026: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) today announced its unaudited financial results for the first quarter ended June 30, 2026. Consolidated Financial Results for Q1 FY27: (Rs. in crores) Y-o-Y Particulars Q1 FY27 Q1 FY26 Grw % Revenue from Operations 668 648 3.0% EBITDA 143 140 1.9% EBITDA Margin 21.4% 21.6% PBT 175 160 9.4% PAT 132 121 9.2% EPS (Rs.) 8.14 7.45 9.2% Revenue from operations for Q1 FY27 stood at Rs. 668 crores, representing a Y-o-Y increase of 3.0% compared with Rs. 648 crores in Q1 FY26. The growth was primarily supported by the performance of International Formulations, particularly the US business, while Domestic Formulations and APIs remained relatively muted during the quarter. EBITDA for Q1 FY27 stood at Rs. 143 crores, compared with Rs. 140 crores in Q1 FY26, reflecting Y-o-Y growth of 1.9%. EBITDA margin was 21.4% during the quarter, compared with 21.6% in the corresponding quarter of the previous year. Profit before tax increased by 9.4% Y-o-Y to Rs. 175 crores, while profit after tax increased by 9.2% Y- o-Y to Rs. 132 crores. Earnings per share stood at Rs. 8.14, compared with Rs. 7.45 in Q1 FY26. Business Segment-wise Sales Performance (Rs. in crores) Particulars Q1 FY27 Y-o-Y Grw % Revenue from Operations 668 3.0% Domestic Formulations 569 -1.9% International Formulations (US) 34 118.4% International Formulations (Non-US) 39 47.7% APIs 24 -2.9% Domestic Formulations: Domestic Formulations revenue stood at Rs. 569 crores in Q1 FY27, reflecting a Y-o-Y decline of 1.9%. Performance was impacted by subdued performance in select key brands, including Zifi, Enerzal and Simyl MCT. Domestic Formulations accounted for approximately 85% of consolidated sales during the quarter. As per secondary sales data from IQVIA for QTR and MAT ended June 30, 2026, the Company recorded growth of 9.0% and 1.9% respectively. International Formulations: International Formulations sales stood at Rs. 73 crores in Q1 FY27, registering Y-o-Y growth of 74.2% and contributing approximately 11% to consolidated sales. The US business reported revenue of Rs. 34 crores, representing Y-o-Y growth of 118.4%, while Non-US Export Formulations revenue stood at Rs. 39 crores, representing Y-o-Y growth of 47.7%. During the quarter, the Company received U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL. APIs: The API business recorded sales of Rs. 24 crores in Q1 FY27, reflecting a Y-o-Y decline of 2.9%, and accounted for approximately 4% of consolidated sales. ABOUT FDC LTD FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmics. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Formulations. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally. Disclaimer Except for the historical information contained herein, statements in this press release and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.